The Department of Justice has been investigating Andreessen Horowitz (a16z) for nearly a year over board seat conflicts involving two of its partners at companies that now compete with each other, invoking a 112-year-old antitrust law rarely used against venture firms. The probe centers on Ben Horowitz sitting on the board of Databricks while Martin Casado holds a board seat at Fivetran, companies that have increasingly moved into each other's markets as their businesses expanded.

What Is the Board Conflict at the Heart of the Investigation?

The arrangement itself may not seem scandalous on the surface. Board conflicts are common in venture capital, and when a16z first invested in both Databricks and Fivetran, they were not necessarily direct competitors. However, as both companies have grown and expanded their product offerings into overlapping areas, the DOJ's scrutiny has intensified. The investigation raises a fundamental question for the venture capital industry: how should firms manage board seats when the boundaries between portfolio companies keep shifting and blurring?

This is not a new problem in venture capital, but the DOJ's decision to invoke antitrust law suggests regulators are taking a harder look at practices that have long been accepted within the industry. The 112-year-old statute being used is rarely deployed against venture firms, making this investigation a potential watershed moment for how the industry operates.

Why Does This Investigation Matter Beyond a16z?

The DOJ's probe signals a broader regulatory shift in how antitrust authorities view venture capital's traditional practices. For decades, venture firms have managed large portfolios where some companies inevitably compete with each other. Partners sitting on multiple boards has been standard practice, seen as a way to share expertise and strategic guidance across investments. But regulators are now questioning whether these arrangements could harm competition or give certain portfolio companies unfair advantages.

For entrepreneurs and limited partners in venture funds, the investigation raises important questions about governance and fairness. If a venture firm's partner sits on the boards of two competing companies, does that create an unfair advantage for one over the other? Could information shared in board meetings inadvertently benefit one company at the expense of another? These concerns, while not new, are now being taken seriously by federal regulators.

How Venture Firms May Need to Adapt

• Board Seat Disclosure: Venture firms may need to more clearly disclose when partners hold board positions at companies that could eventually compete, allowing limited partners and regulators to understand potential conflicts upfront.
• Information Management: Firms could establish clearer protocols to prevent sensitive business information from flowing between competing portfolio companies through shared board members, protecting each company's competitive interests.
• Conflict Monitoring: Venture firms should actively track when portfolio companies begin entering each other's markets and reassess board arrangements accordingly, rather than waiting for regulatory scrutiny to force action.
• Strategic Recusal: Partners may need to recuse themselves from certain board decisions or strategic discussions when conflicts of interest arise, ensuring decisions are made independently rather than influenced by cross-portfolio considerations.

The venture capital industry will likely be watching this investigation closely. The outcome could fundamentally change how venture firms operate their portfolios and manage their relationships with portfolio companies. Even if the investigation concludes without major penalties, the scrutiny itself signals that regulators are watching how venture capital manages potential conflicts between competing investments.